Articles  |   January 2017
SEE Question
Article Information
Neuromuscular Diseases and Drugs / Pharmacology / Articles
Articles   |   January 2017
SEE Question
ASA Monitor 01 2017, Vol.81, 40-41.
ASA Monitor 01 2017, Vol.81, 40-41.
A recently published study evaluated the effects of age and the site of neuromuscular monitoring on reversal of a rocuronium block using sugammadex. Block depth was titrated to a first twitch of 10 percent at the corrugator supercilii while simultaneous neuromuscular monitoring occurred at the adductor pollicis. Based on the results of this study, which of the following is most likely true?
Sugammadex is a unique compound designed as a reversal agent of rocuronium and other steroidal neuromuscular blocking agents. Sugammadex exerts its effect by forming tight complexes with contemporary steroidal neuromuscular blocking drugs (e.g., rocuronium, vecuronium). Sugammadex was recently approved by the U.S. Food and Drug Administration for use in adults for reversal of neuromuscular blockade (NMB) induced by rocuronium and vecuronium only.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large
0 Comments
Submit a Comment
Submit A Comment

Contributors must reveal any conflict of interest. Comments are moderated.

Name
Affiliation & Institution
I have a potential conflict of interest
Comment Title
Comment


This feature is available to Subscribers Only
ASA Member Login or Create an Account ×